Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 78 publications
Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study.
Journal: Journal of the American Academy of Dermatology
Published: February 24, 2026
A randomized, double-blind, phase 3 study to compare efficacy, safety, and immunogenicity between DMB-3115 and reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis.
Journal: JAAD international
Published: September 13, 2025
Richard K. Scher, MD.
Journal: Journal of the American Academy of Dermatology
Published: September 11, 2025
Efficacy and Safety of Risankizumab in Genital or Scalp Psoriasis in the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16.
Journal: Dermatology and therapy
Published: July 25, 2025
Current Practices of Subspecialty Nail Clinics: Results of a Survey of the Members of the Council for Nail Disorders.
Journal: Skin appendage disorders
Published: November 26, 2024
Modern definitions of periungual pigmentation (Hutchinson sign): Results of an expert opinion consensus conference.
Journal: Journal of the American Academy of Dermatology
Published: November 06, 2024
A tribute to Dr Robert Baran: The grandfather of European onychology.
Journal: Journal of the American Academy of Dermatology
Published: April 11, 2024
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis.
Journal: The New England journal of medicine
Published: February 07, 2024
Number of Affected Nails Is the Primary Determinant of Efinaconazole 10% Solution Usage for Onychomycosis.
Journal: Journal of drugs in dermatology : JDD
Published: February 02, 2024
Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks.
Journal: The Journal of dermatological treatment
Published: October 02, 2023
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.
Journal: Journal of the American Academy of Dermatology
Published: June 09, 2023
Last Updated: 09/26/2026